PolyTherics Announces a Research Collaboration with Spirogen to Develop Novel Antibody-Drug Conjugates for the Treatment of Cancer
Under the collaboration, the two companies will produce the ADCs using PolyTherics’ proprietary TheraPEG™ linker technology to site-specifically conjugate Spirogen’s potent pyrrolobenzodiazepines (“PBDs”) cytotoxic agents – known as warheads - to antibodies and antibody fragments. The companies will then test the potency of the resulting ADCs in preclinical models of cancer. PolyTherics and Spirogen will jointly seek partners to develop the most promising ADC candidates that arise from the collaboration.
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.